VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
Key Financial Performance
Total operating expenses Declined 9% compared to the second quarter of 2024, primarily reflecting lower personnel costs and lower research and development expenses.
Net cash used in operating activities (Q2 2025) $6.3 million, compared to $6.7 million in Q2 2024, showing a reduction due to strong cost management.
Net cash used in operating activities (First half of 2025) $10.6 million, down 30% over the same period in the prior year, attributed to cost management.
Revenue (Q2 2025) Over $400,000, contributing to a first half total of over $650,000, with total revenue up 15% in the first half. The increase is attributed to the first revenue from sales of a human product, Nu.Q NETs.
Cash and cash equivalents (End of Q2 2025) Approximately $2.3 million, compared to $3.3 million at the end of 2024. Receipts included $6 million in net proceeds from a convertible loan note and $1.2 million from a registered direct offering post-quarter.
Net loss (First half of 2025) Improved by 24%, reflecting better financial management and reduced expenses.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Nu.Q NETs: First revenue recorded from sales of CE-marked Nu.Q NETs automated product in Europe. Sales have continued in Q2 2025, with 11 hospital networks in 5 countries placing orders. Discussions with over 10 other hospital networks are ongoing.
Nu.Q Cancer: Progress in lung cancer screening study in Taiwan, with interim findings to be presented at ESMO in October. Potential inclusion in national lung cancer screening programs could represent a market exceeding $1 billion annually.
Nu.Q Discover: Serving over 20 clients worldwide, with growing demand for Nu.Q assays as exploratory biomarkers in clinical trials. Largest project projected revenue in hundreds of thousands of dollars.
Licensing Agreements: Confidential discussions with over 10 companies, including 7 with a combined market value exceeding $600 billion. Goal to secure multiple licensing agreements in human diagnostics, mirroring veterinary success.
Global Expansion: Potential inclusion of Nu.Q Cancer in national lung cancer screening programs in Taiwan, U.S., U.K., and France. Expansion of Nu.Q NETs sales to more hospital networks globally.
Cost Management: Total operating expenses declined 9% in Q2 2025 compared to Q2 2024. Net cash used in operating activities reduced by 30% in the first half of 2025.
Revenue Growth: Revenue increased by 15% in the first half of 2025, with total revenue reaching over $650,000. First revenue recorded for sales of human product Nu.Q NETs.
Commercialization Focus: 2025 is focused on commercializing the Nu.Q platform in human diagnostics. Progress in licensing discussions and clinical validations to support commercialization.
Technology Platform: Nu.Q platform demonstrated versatility across cancer, sepsis, and veterinary applications. Positioned for broad applicability and potential partnerships.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue unpredictability: Revenues remain fairly lumpy and difficult to predict from one quarter to the next, making financial forecasting challenging.
Cash reserves: Cash and cash equivalents at the end of the quarter totaled approximately $2.3 million, which is a decline from $3.3 million at the end of 2024, indicating potential liquidity concerns.
Dependence on licensing agreements: Achieving cash neutrality for 2025 is dependent on executing one or more licensing agreements in the human space with significant upfront payments, which introduces uncertainty.
Regulatory hurdles: The company is navigating regulatory filings under the IVDR framework, which could delay product approvals and commercialization.
Market adoption challenges: The adoption of Nu.Q tests into national lung cancer screening programs and routine clinical practice is not guaranteed and depends on positive study results and government approvals.
Competitive pressures: The company is operating in highly competitive markets, including cancer diagnostics and sepsis, with other players potentially offering alternative solutions.
Economic uncertainties: The company’s financial health and ability to secure licensing deals may be impacted by broader economic conditions.
Product validation and scalability: The success of the Nu.Q platform depends on the validation of ongoing studies and the scalability of its technology for widespread adoption.
Dependence on partnerships: The company’s strategy heavily relies on partnerships with large companies and hospital networks, which may not materialize as expected.
Supply chain and operational risks: The company is focused on central lab automation and scaling up production, which could face operational or supply chain challenges.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance: The company will not be providing revenue guidance for 2025 at this point in time due to the early stage of commercialization and the unpredictable nature of revenues.
Cash Neutrality Goal: One of the key financial goals for 2025 is to be cash neutral on a full-year basis. This depends on executing one or more licensing agreements in the human space with significant upfront payments, receiving milestone payments in the veterinary space, and reducing expenditures.
Licensing Agreements: The company is in confidential discussions with over 10 companies, aiming to secure multiple licensing agreements in the human diagnostic space. These agreements are expected to include ongoing revenue and large milestone payments.
Nu.Q Cancer Test: The final lung cancer screening study in Taiwan is progressing rapidly, with interim analysis to be presented in October 2025. Positive findings could position the Nu.Q test for inclusion in national lung cancer screening programs, representing a potential market exceeding $1 billion annually across Taiwan, U.S., U.K., and France.
Nu.Q NETs Test: The company is progressing with the commercialization of the Nu.Q NETs test, with 11 hospital networks in 5 countries currently assessing its clinical utility. Licensing discussions are ongoing, with the total addressable market for the Nu.Q NETs assay estimated to exceed $10 billion annually.
Nu.Q Discover: The Nu.Q Discover platform is serving over 20 clients worldwide and is expected to see strong revenue growth in 2025. The company is exploring co-marketing partnerships to meet global demand.
Strategic Focus for 2025: The company is focused on signing licensing deals in the human diagnostic space, progressing discussions with national lung screening programs, and commercializing its technology to make it accessible worldwide.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on which uses of the Nu.Q platform have been attracting the most attention from potential partners in the human health space?
A:Cameron Reynolds stated that interest is coming from almost every area of the Nu.Q platform. He highlighted the Discover side with over 20 clients, including major companies, and the NETosis space with large diagnostic, autoimmune, and coagulation companies. The CE marked kit is being used by 11 hospital networks in 5 countries for 21 use cases. Oncology, particularly lung screening programs, has seen renewed interest, and discussions are ongoing with large liquid biopsy companies. Reynolds emphasized the platform's stability, low cost, and adaptability, and mentioned being close to finalizing the first human out-licensing deal.
Q:Are you starting to see repeat customers as you're making some of the sales of Nu.Q NETs in Europe?
A:Yes, Cameron Reynolds confirmed that multiple hospital networks have placed repeat orders, with some on their third or fourth reorders. He noted that customers appreciate the adaptability and effectiveness of the test, and there is also interest in purchasing basic microtiter plates for independent research.
Q:As you execute a deal and bring real capital into the company, how do you use that capital?
A:Reynolds explained that the goal is to become revenue neutral. Deals in the vet, NETs, Discover, and human spaces will vary in size, with some generating large payments and ongoing revenues. He mentioned Fuji's progress on validating the centralized lab for the i10 machine in the vet space, which could lead to wellness panels for dogs and significantly increase test volumes.
Q:Could you provide some color on the indication or application of the first human deal? Will future human application deals be mutually exclusive in terms of application or indication?
A:Reynolds did not disclose specific details about the first human deal due to confidentiality but mentioned that all deals depend on the use of their test. He noted that deals will vary in size and scope, with some involving co-marketing and others targeting national screening programs. He expects a steady stream of deals through next year, with timelines for commercialization ranging from immediate to 3-4 years.
Q:Could you provide some rough estimates as to the length of time required for your customers typically between licensing the deal to commercialization?
A:Reynolds stated that timelines vary: co-marketing Discover deals can generate immediate revenue, while vet space deals are quicker due to simpler regulatory processes. Human applications requiring CE mark or FDA approval take 2-3 years. Some platforms have already been adapted, reducing timelines to 6-12 months for certain cases.
Q:With the Taiwan screening program, are they prepared to scale that type of a program? Do you have the test on a high-volume analyzer right now to do that in Taiwan?
A:Reynolds confirmed that the test is on the required machine and that trials are in the final validation stage. He mentioned the possibility of launching in a CLIA lab for early revenue and pursuing Taiwanese FDA approval for broader adoption. Revenue generation could begin in the first half of next year, depending on trial results.
Q:In Taiwan, in addition to the Taiwanese FDA, are there any other regulatory or guideline bodies that would need to sign off on using the test before it went into full production?
A:Reynolds stated that no additional regulatory bodies are currently required beyond the Taiwanese FDA. He mentioned that the test could be launched in a CLIA lab setting for direct sales revenue, potentially around $50 per test, if trials continue to show positive results.
Q:Was the lateral flow test for NETs an internally developed platform, or did you work with a partner on that?
A:Reynolds mentioned working with several external partners on the lateral flow test, which has shown promising results. The test is quantitative and works well with venous blood, with ongoing work for capillary blood. He highlighted its potential for direct sales and low production costs, making it a lucrative addition to their revenue stream.
Q:Review of Unclear Management Responses
A:Management avoided directly answering the question about which specific use of the Nu.Q platform is attracting the most attention, instead stating that interest is broad across all areas. Additionally, they did not disclose details about the first human deal, citing confidentiality, and provided only general timelines for commercialization without specific data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Benchmark LLC
Berlin Chief
Boral Capital
Brighter Tomorrow
Bruce Jackson
CEO President
CFO Treasurer
CT scan
Capital LLC
Care care
Cash progress
Chen HC
Chief Commercial
Chief Medical
Chief Scientific
Civils Lyon
Clinical Oncology
Howard
LLC Research
Medical Officer
NETs pillar
Research Division
VolitionRx Limited
adoption
biopsy
condition
decision
journal
patient cancer
patient risk
patient study
peer review
rule
validation
VNRX Transcript
VolitionRx Limited (VNRX) Q1 2026 Earnings Call Transcript
Unknown5-15
The earnings call summary shows positive financial metrics such as a 25% revenue increase and improved net loss, gross margin, and cash flow. However, the absence of strategic initiatives, operational updates, and return discussions, coupled with the acknowledgment of risks in forward-looking statements, balances the sentiment. Without additional insights from the Q&A section, the sentiment remains neutral, lacking strong catalysts for significant stock price movement.
VolitionRx Limited (VNRX) Q4 2025 Earnings Call Transcript
Positive4-1
The earnings call reveals a strong financial performance with significant revenue growth and reduced expenses, indicating improved operational efficiency. Despite uncertainties in licensing agreements and future funding, the company has secured substantial nondilutive funding, mitigating immediate financial concerns. The Q&A indicates potential for growth through partnerships and global expansion, though management's lack of specific guidance introduces some uncertainty. Overall, the company's strategic developments and financial improvements suggest a positive outlook for the stock price in the short term.
VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript
Unknown11-14
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript
Positive8-15
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
VNRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
